
Shares of drugmaker Biogen BIIB.O rise 1.26% to $187.69 premarket
Co sees 2026 adj. profit of $15.25-$16.25/shr, above Wall Street's estimate of $14.92
Reports Q4 adj. profit of $1.99/shr vs analysts' average estimate of $1.59/shr - LSEG data
Quarterly revenue $2.3 bln vs analysts' average expectation of $2.2 bln
Shares up ~15% in 2025